AnaptysBio Prepares for a Potential Gear Shift

There wasn t much financial activity to report during the second quarter of 2019 but it was still a rough one for AnaptysBio NASDAQ ANAB and its lead candidate etokimab Positive midstage clinical trial results that the company announced in early June didn t ignite any fireworks

Leave a Reply

Your email address will not be published. Required fields are marked *